These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Adverse events reported in oncology clinical trials don’t always match what patients experience. What is behind this ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

U.S. District Judge John Cronan in New York declined to grant a preliminary injunction on the funding freeze while the case is winding through the courts. Plus, President Trump's One Big Beautiful ...